SEARCH:   Advanced

Blood, Vol. 109, Issue 11, 5011-5015, June 1, 2007 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study Blood Ray et al. 109: 5011 Supplemental materials for: Ray et al, Vol 109, Issue 11, 5011-5015 Files in this Data Supplement: Table S1. List of different multiple point mutations recovered in the random mutagenesis study (PDF, 13.8 KB) Figure S1. Western blot of whole-cell lysates from different Ba/F3 cell lines expressing wild-type and mutant Bcr-Abl proteins (JPG, 52.3 KB) - Lysates were probed with anti–c-abl (top panel; MW, 210 kDa) and -tubulin (bottom panel; MW, 55 kDa) antibodies. Figure S2. Mapping of mutants in terms of their IC50 values (JPG, 39.1 KB) - The point mutants recovered from the screen and validated are mapped in different regions of the kinase domain of Bcr-Abl in terms of the range of IC50 values shown in the side panel. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020